SCHEMBL1542446

SCHEMBL1542446

COc1c(NC(=O)c2ccc(NCC(F)(F)F)cc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.48
ABL1 P00519 1/20 0.43
TP53 P04637 2/20 0.40
MAPT P10636 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
BTK Q06187 1/20 0.39
NR1H4 Q96RI1 2/20 0.37
KIT P10721 1/20 0.36
SRC P12931 1/20 0.36
FLT3 P36888 1/20 0.36
ITK Q08881 1/20 0.36
HDAC1 Q13547 1/20 0.36
UGCG Q16739 1/20 0.36
PARP1 P09874 1/20 0.36
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36
CD274 Q9NZQ7 1/20 0.36
CYP2C19 P33261 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1542911 0.91 CYP3A4 (0.49) CYP3A4ABL1TP53MAPTSMN1; SMN2
SCHEMBL1542355 0.89 CYP3A4 (0.43) CYP3A4ABL1SMN1; SMN2BTKKIT
SCHEMBL2128418 0.87 CYP3A4 (0.49) CYP3A4ABL1TP53MAPTSMN1; SMN2
SCHEMBL2489637 0.86 KIT (0.38) CYP3A4ABL1TP53MAPTSMN1; SMN2
SCHEMBL1542657 0.86 CYP3A4 (0.49) CYP3A4ABL1TP53MAPTSMN1; SMN2
SCHEMBL1542748 0.85 CYP3A4 (0.47) CYP3A4ABL1TP53MAPTSMN1; SMN2
SCHEMBL1542369 0.84 CYP3A4 (0.65) CYP3A4ABL1TP53MAPTSMN1; SMN2
SCHEMBL1543037 0.84 CYP3A4 (0.49) CYP3A4ABL1TP53MAPTSMN1; SMN2
SCHEMBL1542768 0.84 CYP3A4 (0.42) CYP3A4ABL1BTKCD274CYP2C19
SCHEMBL1543460 0.81 CYP3A4 (0.44) CYP3A4ABL1TP53MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US claimed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP claimed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US disclosed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP disclosed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP disclosed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO disclosed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885ABL1 584/4885TP53 1313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.